• 목록
• 답변
• 글쓰기
• 게시판 리스트 옵션
  • 수정
  • 삭제

Summary: This observational study evaluated the efficacy and tolerability of tretinoin gel 0.025% in a real-world setting among patients with acne vulgaris. Data was retroactively assembled from patient documents at a dermatology facility over 12 months. The principal outcome measures encompassed variations in acne lesion counts (inflammatory and non-inflammatory) and patient-reported endurance. Results revealed a significant lessening in both inflammatory and non-inflammatory lesions post 12 weeks of treatment. Though early irritation was typical, it typically subsided within the first couple of weeks. This research backs the ongoing application of tretinoin gel 0.025% as a potent and mostly well-accepted therapy choice for acne vulgaris in practical clinical environments.

Opening: Acne vulgaris is a prevalent ongoing inflammatory skin issue affecting a notable fraction of the international population, primarily teenagers and young adults. Treatment options vary widely, ranging from topical retinoids to oral antibiotics and systemic therapies. Tretinoin, as a topical retinoid, remains a broadly applied and firmly established therapy for acne owing to its capacity to lower sebum output, encourage epidermal cell renewal, and lessen inflammation. Although many clinical studies have shown the effectiveness of tretinoin, practical observational research is essential to evaluate its performance and acceptability in varied patient groups and in standard medical practice settings. This research intended to backwardly examine the medical results and tolerance of tretinoin gel 0.025% in individuals with acne vulgaris cared for at a skin clinic.

Methodology: This retrospective observational study included adult patients (18 years and older) diagnosed with acne vulgaris who were prescribed tretinoin gel 0.025% as a primary treatment modality between January 1, 2022, and December 31, 2022, at a single dermatology clinic. Patient records were examined to gather information on demographics (age, gender), baseline acne intensity (evaluated via a modified Global Acne Grading System [mGAGS]), therapy length, alterations in lesion numbers (inflammatory and non-inflammatory) at starting point, 4 weeks, 8 weeks, and 12 weeks, and patient-noted tolerance (evaluated through doctor notes recording patient issues). Data on concomitant medications were also recorded.

The mGAGS score was established by aggregating the values for inflammatory lesions (papules, pustules, nodules, cysts) and non-inflammatory lesions (comedones). Each lesion kind was attributed a score grounded on its harshness and amount. Tolerability was assessed based on clinician documentation of patient-reported adverse events, including dryness, irritation, erythema, and peeling. The intensity of these negative events was classified as mild, moderate, or severe.

Statistical evaluation was conducted employing descriptive statistics to outline the demographic and clinical features of the research group. Paired t-tests were used to assess lesion figures at baseline and at every subsequent time point. Variations in lesion counts were furthermore analyzed via repeated measures ANOVA. The association between baseline acne severity and treatment response was assessed using correlation analysis.

Outcomes: A total of 100 patients (62 females, 38 males) with a mean age of 24.5 ± 5.2 years were included in the study. The mean baseline mGAGS score was 18.7 ± 6.3. At starting, the average count of inflammatory lesions was 9.2 ± 4.1 and the average count of non-inflammatory lesions was 9.5 ± 3.8.

Significant reductions in both inflammatory and non-inflammatory lesion counts were observed at all follow-up time points compared to baseline (p<0.001 for all comparisons). The typical drop in inflammatory lesions at 12 weeks was 7.1 ± 2.9, and the typical drop in non-inflammatory lesions was 6.8 ± 2.7. Repeated measures ANOVA displayed a marked time outcome on both inflammatory and non-inflammatory lesion figures (p<0.001 for both).

Beginning irritation was indicated by 72% of patients, with the greater part experiencing mild irritation (60%). Moderate irritation was reported by 12% of patients, and severe irritation was reported by merely 10% of patients. Most patients with mild to moderate irritation noted clearing of symptoms in 4 weeks of starting therapy. No patients discontinued treatment due to intolerability.

Discussion: This study presents real-life evidence promoting the efficiency and endurance of tretinoin gel 0.025% in treating acne vulgaris. The marked reduction in both inflammatory and non-inflammatory lesion figures identified in this report is consistent with data from former clinical trials. The high rate of initial irritation is also consistent with the known side effect profile of tretinoin. However, the fact that the majority of patients experienced only mild irritation and that the irritation generally resolved within a few weeks suggests that tretinoin gel 0.025% is generally well-tolerated.

The retrospective nature of this study is a limitation, as it is susceptible to potential biases related to data collection and missing data. Additionally, the investigation was performed at a single facility, which might constrain the generalizability of the findings to different populations. Upcoming forward-looking studies with bigger sample groups and several centers are required to additionally verify these results.

Conclusion: This observational study supports the use of tretinoin gel 0.025% as an effective and generally well-tolerated treatment for acne vulgaris in a real-world clinical setting. Although starting irritation is frequent, it is typically mild and temporary. Doctors ought to inform patients regarding the possibility of early irritation and recommend methods to alleviate these adverse effects. Further research is warranted to explore the long-term efficacy and safety of tretinoin gel 0.025% in diverse populations.